• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP.接受来那度胺作为R-CHOP方案后维持治疗的弥漫性大B细胞淋巴瘤（DLBCL）患者中枢神经系统复发的发生率
Blood Adv. 2021 Aug 10;5(15):2965-2968. doi: 10.1182/bloodadvances.2021004766.
2
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?来那度胺用于复发或难治性弥漫性大B细胞淋巴瘤：它是一种有效的治疗选择吗？
Oncologist. 2016 Sep;21(9):1107-12. doi: 10.1634/theoncologist.2016-0103. Epub 2016 Jul 5.
3
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.来那度胺维持治疗不适用于自体干细胞移植的复发弥漫性大B细胞淋巴瘤患者：一项开放标签、单臂、多中心2期试验。
Lancet Haematol. 2017 Mar;4(3):e137-e146. doi: 10.1016/S2352-3026(17)30016-9. Epub 2017 Feb 17.
4
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation.来那度胺维持治疗不适合或自体移植失败的复发弥漫性大 B 细胞淋巴瘤患者的长期疗效和安全性。
Hematol Oncol. 2020 Aug;38(3):257-265. doi: 10.1002/hon.2742. Epub 2020 May 5.
5
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.来那度胺维持治疗对比安慰剂用于一线利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗的老年弥漫性大 B 细胞淋巴瘤患者。
J Clin Oncol. 2017 Aug 1;35(22):2473-2481. doi: 10.1200/JCO.2017.72.6984. Epub 2017 Apr 20.
6
Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.弥漫性大 B 细胞淋巴瘤患者中枢神经系统复发的发生率和危险因素：利妥昔单抗联合 CHOP 化疗的影响。
Ann Oncol. 2010 May;21(5):1046-52. doi: 10.1093/annonc/mdp432. Epub 2009 Oct 27.
7
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.来那度胺治疗预处理弥漫大 B 细胞淋巴瘤患者：意大利真实世界多中心回顾性研究。
Oncologist. 2019 Sep;24(9):1246-1252. doi: 10.1634/theoncologist.2018-0603. Epub 2019 Apr 2.
8
Sanctuary site central nervous system relapse-refractory DLBCL responding to nivolumab and lenalidomide.尼伏单抗和来那度胺治疗庇护所部位中枢神经系统复发难治弥漫性大 B 细胞淋巴瘤。
Oral Oncol. 2019 Jun;93:122-124. doi: 10.1016/j.oraloncology.2019.04.010. Epub 2019 Apr 19.
9
Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.弥漫性大 B 细胞淋巴瘤和套细胞淋巴瘤的维持治疗。
Curr Treat Options Oncol. 2018 Jul 21;19(9):45. doi: 10.1007/s11864-018-0561-x.
10
New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.弥漫性大B细胞淋巴瘤患者中枢神经系统复发的新危险因素及新趋势：一项回顾性研究
Chin J Cancer. 2016 Sep 13;35(1):87. doi: 10.1186/s40880-016-0150-y.

引用本文的文献

1
Relapsed isolated CNS lymphoma treated with radiotherapy and intrathecal methotrexate followed by high-dose intravenous methotrexate, rituximab, and temozolomide: A case report.复发性孤立性中枢神经系统淋巴瘤采用放疗和鞘内注射甲氨蝶呤治疗，随后给予大剂量静脉注射甲氨蝶呤、利妥昔单抗和替莫唑胺：一例报告。
Clin Case Rep. 2024 Mar 1;12(3):e8409. doi: 10.1002/ccr3.8409. eCollection 2024 Mar.
2
Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma.弥漫大 B 细胞淋巴瘤缓解患者接受来那度胺维持治疗的真实世界数据。
Cancer Med. 2023 May;12(9):10553-10562. doi: 10.1002/cam4.5790. Epub 2023 Mar 13.
3
Prevention and management of secondary central nervous system lymphoma.继发性中枢神经系统淋巴瘤的预防和治疗。
Haematologica. 2023 Mar 1;108(3):673-689. doi: 10.3324/haematol.2022.281457.

本文引用的文献

1
Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma.基因组亚型可能预测弥漫性大B细胞淋巴瘤中枢神经系统复发的风险。
Blood. 2021 Feb 25;137(8):1120-1124. doi: 10.1182/blood.2020007236.
2
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery.弥漫性大 B 细胞淋巴瘤中高剂量甲氨蝶呤中枢神经系统预防的时机：毒性分析及其对 R-CHOP 给药的影响。
Blood Adv. 2020 Aug 11;4(15):3586-3593. doi: 10.1182/bloodadvances.2020002421.
3
Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review.利妥昔单抗时代采用蒽环类化疗治疗弥漫性大 B 细胞淋巴瘤患者时，单纯鞘内化疗的中枢神经系统预防效果：系统评价。
Haematologica. 2020 Jul;105(7):1914-1924. doi: 10.3324/haematol.2019.229948. Epub 2019 Sep 5.
4
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.来那度胺联合静脉利妥昔单抗（REVRI）治疗复发/难治性原发性中枢神经系统淋巴瘤或原发性眼内淋巴瘤：法国眼脑淋巴瘤（LOC）网络和淋巴瘤研究协会（LYSA）的多中心前瞻性“概念验证”二期研究†。
Ann Oncol. 2019 Apr 1;30(4):621-628. doi: 10.1093/annonc/mdz032.
5
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.将起源细胞纳入临床中枢神经系统国际预后指数可改善弥漫性大 B 细胞淋巴瘤中枢神经系统复发的预测。
Blood. 2019 Feb 28;133(9):919-926. doi: 10.1182/blood-2018-07-862862. Epub 2019 Jan 7.
6
Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.来那度胺/利妥昔单抗联合来那度胺维持治疗复发性中枢神经系统淋巴瘤的 1 期研究结果。
Blood Adv. 2018 Jul 10;2(13):1595-1607. doi: 10.1182/bloodadvances.2017014845.
7
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.来那度胺维持治疗对比安慰剂用于一线利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗的老年弥漫性大 B 细胞淋巴瘤患者。
J Clin Oncol. 2017 Aug 1;35(22):2473-2481. doi: 10.1200/JCO.2017.72.6984. Epub 2017 Apr 20.
8
The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.通过PET/CT扫描评估的结外部位数量是弥漫性大B细胞淋巴瘤患者中枢神经系统复发的有力预测指标：一项对1532例接受化疗免疫治疗患者的国际多中心研究。
Eur J Cancer. 2017 Apr;75:195-203. doi: 10.1016/j.ejca.2016.12.029. Epub 2017 Feb 23.
9
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.CNS 国际预后指数：R-CHOP 治疗弥漫性大 B 细胞淋巴瘤患者 CNS 复发的风险模型。
J Clin Oncol. 2016 Sep 10;34(26):3150-6. doi: 10.1200/JCO.2015.65.6520. Epub 2016 Jul 5.
10
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.来那度胺在B细胞非霍奇金淋巴瘤中的作用机制
J Clin Oncol. 2015 Sep 1;33(25):2803-11. doi: 10.1200/JCO.2014.59.5363. Epub 2015 Jul 20.

Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP.

作者信息

Bernard Sophie, Ghesquieres Herve, Casasnovas Rene-Olivier, Griolet Samuel, Gomes da Silva Maria, Feugier Pierre, Morschhauser Franck, Trotman Judith, Renaud Loic, Greil Richard, García-Sancho Alejandro Martín, Grosicki Sebastian, van Eygen Koen, Copie-Bergman Christiane, Haioun Corinne, Thieblemont Catherine

机构信息

Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Hemato-Oncologie, Paris, France.

Hôpital Lyon Sud, Hématologie, Pierre-Benite, France.

出版信息

Blood Adv. 2021 Aug 10;5(15):2965-2968. doi: 10.1182/bloodadvances.2021004766.

DOI:10.1182/bloodadvances.2021004766
PMID:34338754
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC8361464/
Abstract
摘要